|
| |
| CytRx Corporation
CytRx Corporation (NASDAQ: CYTR), is a biopharmaceutical company engaged in the development of high-value human therapeutics.
In addition to its drug development pipeline, the Company owns and operates a research and development facility in San Diego dedicated to the discovery of new drug candidates based on the Company's small molecule chaperone regulation technology. CytRx also maintains a 45% equity interest in RXi Pharmaceuticals (Nasdaq: RXII).
About CytRx Corp >
News & Events >
Investor Relations >
Careers >
Contact Us >
| | Development Pipeline
CytRx's drug development pipeline includes five programs in clinical development, including tamibarotene in registration studies for the treatment of acute promyelocytic leukemia (APL). In addition to a portfolio of oncology programs, CytRx is developing two drug candidates based on the Company’s proprietary molecular chaperone technology which aims to repair or degrade misfolded proteins associated with disease.
Molecular Chaperone Regulation >
Oncology Portfolio > |
| News & Events
12/03/2008 CytRx Unveils Clinical Development Plan for Pipeline Assets More
11/11/2008 INNO-406 Demonstrates Positive Clinical Responses in Phase 1 Trial in Patients with Chronic Myeloid Leukemia More
11/10/2008 CytRx Corporation Announces 2008 Third Quarter Financial Results
More
11/5/2008 CytRx Corporation to Present at the Rodman & Renshaw Annual Healthcare Conference More
See more press releases > |  Webcasts
11/11/2008 CytRx Corp. at Rodman & Renshaw Annual Healthcare Conference
More | 
|
|
| |
| |
|
